CSPC Pharmaceutical Group (1093)
7.62 HKD +0.80 (+11.73%) Volume: 417.5M
CSPC Pharmaceutical Group’s stock price soars to 7.62 HKD, marking a significant trading session increase of +11.73% with a high trading volume of 417.5M, and an impressive YTD performance, up by +59.41%, reflecting robust investor confidence in the stock.
Latest developments on CSPC Pharmaceutical Group
CSPC Pharmaceutical Group has reported a decline in its Q1 2025 results, with net profit slipping by 8.4% to RMB1.478 billion. This decrease comes amid industry challenges that the company has been facing in the pharmaceutical sector. The stock price movements today reflect investor reactions to these financial results, as well as the broader market conditions impacting the company’s performance.
A look at CSPC Pharmaceutical Group Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 4.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores for CSPC Pharmaceutical Group, the company appears to have a positive long-term outlook. With high scores in Dividend and Momentum, investors may see potential for steady returns and growth in the future. Additionally, strong scores in Value and Resilience indicate that the company is well-positioned to weather market fluctuations and maintain its value over time.
CSPC Pharmaceutical Group Limited, known for manufacturing and selling a variety of pharmaceutical products including vitamin C, antibiotics, and generic drugs, seems to be on a solid path for continued success. The company’s focus on developing innovative drugs and antibiotics further adds to its potential for growth and sustainability in the competitive pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
